PYXS
Pyxis Oncology, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Pyxis Oncology (PYXS) Stock: Buy, Sell, or Hold?
$1.62
-0.01 (-0.61%)
▼
5d:
-2.41%
30d:
-12.43%
90d:
-46.18%
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (80%)
Quality Score
53/100
Position
OVERSOLD
30-Day Fair Range
$1.65 – $1.96
Position: OVERSOLD
Forward P/E & Valuation
-1.9x
Next 12M consensus est.
Wall Street Target
$8.22
+404.4% upside
Options IV & Volume
52th pct IV
HIGH volume confirmation
Support / Resistance
$1.50 / $1.99
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: PYXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $1.62, which is considered oversold relative to its 30-day fair value range of $1.65 to $1.96.
Technical Outlook: Technically, PYXS is in a downtrend. Immediate support is located at $1.50, while resistance sits at $1.99.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.22 (+404.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PYXS is in a downtrend. Immediate support is located at $1.50, while resistance sits at $1.99.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.22 (+404.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.65 -
$1.96
Company Quality Score
53/100
(HOLD)
Options IV Signal
52th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
Trading Range & Key Levels
30-Day Trading Range
$1.65 -
$1.96
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.59
(36.6%)
Support Level
$1.50
Resistance Level
$1.99
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 52th percentile)
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 404.4% below Wall St target ($8.22)
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$8.22
(+404.4%)
Share PYXS Analysis
Share this live PYXS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PYXS)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 9, 2026
Daily AI digest
AI Retail Discussion Summary:
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Pyxis Oncology (PYXS) with a price target of $8.00.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 2:43 PM ET
Data refreshes hourly during market hours. Next update: 3:43 PM
Data refreshes hourly during market hours. Next update: 3:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 56 HOLD |
|
RZLT
Rezolute Inc |
STRONG BUY
11 analysts |
$10 | 72 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PYXS Research Pages
